Latest Period
Q1 2026
Security Snapshot
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) Institutional Ownership
CUSIP: 89532M101
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
196
Shares (Excl. Options)
134,909,054
Price
$11.93
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- TRVI on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 134,909,054
- Total 13F value
- $1,611,173,952
- Portfolio coverage rank
- 0%
- Share change
- +3,919,310
- Value change
- +$44,966,485
- Number of holders
- 196
- Shares outstanding
- 143,562,667
- SEC-reported price per share
- $15.27
- Insider filing price
- $15.27
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 89532M101.
- 196 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 185 to 196 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,631,941,846 to $1,611,173,952.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 196 institutions filings for Q1 2026.
Security key
89532M101
Latest holder period
Q1 2026
13F holders
196
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
TRVI full holder history
Trevi Therapeutics, Inc. SEC filings
Trevi Therapeutics, Inc. company facts
Trevi Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 89532M101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
TRVI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 10% | -9.2% | $198,827,115 | 15,074,080 | 0% | New Enterprise Associates 16, L.P. | 05 May 2026 | |
| Frazier Life Sciences Public Fund, L.P. | 7% | -33% | $77,848,392 | -$16,025,200 | 8,508,021 | -17% | Frazier Life Sciences Public Fund, L.P. | 30 Sep 2025 |
| FMR LLC | 6.3% | +24% | $106,022,020 | +$20,286,893 | 8,038,061 | +24% | FMR LLC | 31 Mar 2026 |
| BlackRock, Inc. | 5.6% | $62,259,693 | 6,804,338 | BlackRock, Inc. | 30 Sep 2025 | |||
| VIKING GLOBAL INVESTORS LP | 4.2% | -28% | $46,929,206 | -$21,747,894 | 5,128,875 | -32% | VIKING GLOBAL INVESTORS LP | 30 Sep 2025 |
| Rubric Capital Management LP | 2.9% | -60% | $42,526,596 | -$53,798,103 | 3,766,749 | -56% | Rubric Capital Management LP | 31 Dec 2025 |
| Venrock Healthcare Capital Partners II, L.P. | 1.4% | $8,042,002 | 1,266,457 | Venrock Healthcare Capital Partners II, L.P. | 31 Dec 2024 | |||
| Rosalind Advisors, Inc. | 1.2% | $6,746,875 | 1,062,500 | Rosalind Advisors, Inc. | 13 Feb 2025 |
As of 31 Mar 2026, 196 institutional investors reported holding 134,909,054 shares of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI). This represents 94% of the company’s total 143,562,667 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
71%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 9.2% | 13,222,228 | 0% | 9% | $157,741,180 |
| BlackRock, Inc. | 7.1% | 10,240,186 | +1.1% | 0% | $122,165,419 |
| Frazier Life Sciences Management, L.P. | 6.9% | 9,939,547 | -3.1% | 3.1% | $118,578,796 |
| FMR LLC | 5.6% | 8,038,061 | +24% | 0.01% | $95,894,063 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.6% | 5,189,088 | +52% | 0.01% | $61,905,820 |
| Vivo Capital, LLC | 3.5% | 5,094,668 | 0% | 5.1% | $60,779,389 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 4,978,567 | 0% | 0% | $59,394,304 |
| MARSHALL WACE, LLP | 2.8% | 3,966,019 | -13% | 0.05% | $47,314,607 |
| Rubric Capital Management LP | 2.6% | 3,712,373 | -1.4% | 0.54% | $44,288,610 |
| MPM BIOIMPACT LLC | 2.3% | 3,298,430 | +0.35% | 3% | $39,350,270 |
| VIKING GLOBAL INVESTORS LP | 2.2% | 3,198,644 | 0% | 0.11% | $38,159,823 |
| ALLIANCEBERNSTEIN L.P. | 2% | 2,845,472 | -7.7% | 0.01% | $35,625,309 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 2,778,231 | +15% | 0% | $33,150,121 |
| STATE STREET CORP | 1.9% | 2,665,313 | +9.5% | 0% | $31,797,184 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.8% | 2,622,306 | 0% | 0.52% | $31,284,111 |
| ORBIMED ADVISORS LLC | 1.7% | 2,454,400 | -23% | 0.66% | $29,280,992 |
| Logos Global Management LP | 1.7% | 2,400,000 | +55% | 1.5% | $28,632,000 |
| Vestal Point Capital, LP | 1.5% | 2,166,504 | 0.72% | $25,846,393 | |
| ACORN CAPITAL ADVISORS, LLC | 1.5% | 2,144,844 | 0% | 7.3% | $25,587,989 |
| Artia Global Partners LP | 1.4% | 2,013,602 | 0% | 5.4% | $24,022,272 |
| Affinity Asset Advisors, LLC | 1.4% | 2,000,172 | -7% | 1.4% | $23,862,052 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1.4% | 1,994,292 | +80% | 0.24% | $23,791,904 |
| EMERALD ADVISERS, LLC | 1.3% | 1,839,566 | -2.8% | 0.69% | $21,946,022 |
| Siren, L.L.C. | 1.2% | 1,786,867 | -22% | 0.59% | $21,317,323 |
| Pictet Asset Management Holding SA | 1.2% | 1,706,048 | +11% | 0.02% | $20,353,153 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
28
Latest
Q1 2026
Rows shown
1-25 of 28
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 134,909,054 | $1,611,173,952 | +$44,966,485 | $11.93 | 196 |
| 2025 Q4 | 130,345,518 | $1,631,941,846 | +$9,116,093 | $12.52 | 185 |
| 2025 Q3 | 129,323,951 | $1,183,258,435 | +$141,190,764 | $9.15 | 163 |
| 2025 Q2 | 114,653,135 | $627,154,153 | +$139,569,505 | $5.47 | 153 |
| 2025 Q1 | 88,130,237 | $554,340,184 | +$59,175,189 | $6.29 | 137 |
| 2024 Q4 | 79,496,969 | $329,526,035 | +$80,359,022 | $4.12 | 109 |
| 2024 Q3 | 58,119,888 | $194,118,470 | +$7,244,002 | $3.34 | 92 |
| 2024 Q2 | 55,906,669 | $166,602,895 | +$12,771,260 | $2.98 | 76 |
| 2024 Q1 | 51,561,502 | $177,886,781 | -$90,828 | $3.45 | 79 |
| 2023 Q4 | 52,233,706 | $69,993,370 | -$4,018,362 | $1.34 | 62 |
| 2023 Q3 | 48,682,678 | $106,127,667 | -$321,362 | $2.18 | 55 |
| 2023 Q2 | 48,822,080 | $116,683,910 | +$12,840,858 | $2.39 | 53 |
| 2023 Q1 | 43,462,507 | $80,405,139 | +$498,873 | $1.85 | 35 |
| 2022 Q4 | 43,185,947 | $83,348,629 | -$3,845,159 | $1.93 | 36 |
| 2022 Q3 | 45,770,959 | $70,490,000 | +$26,192,291 | $1.54 | 37 |
| 2022 Q2 | 28,751,331 | $80,790,000 | +$28,742,730 | $2.81 | 31 |
| 2022 Q1 | 7,161,506 | $15,754,000 | +$2,083,345 | $2.20 | 20 |
| 2021 Q4 | 13,166,532 | $10,286,000 | -$218,769 | $0.78 | 15 |
| 2021 Q3 | 12,448,249 | $17,424,000 | -$63,952 | $1.40 | 15 |
| 2021 Q2 | 12,478,497 | $28,076,000 | -$1,746,455 | $2.25 | 15 |
| 2021 Q1 | 13,128,768 | $35,591,000 | +$338,711 | $2.71 | 17 |
| 2020 Q4 | 13,007,586 | $31,748,000 | -$644,938 | $2.42 | 17 |
| 2020 Q3 | 13,263,517 | $53,451,000 | -$728,128 | $4.03 | 13 |
| 2020 Q2 | 13,374,829 | $88,003,000 | -$1,315,702 | $6.58 | 12 |
| 2020 Q1 | 13,964,620 | $45,943,000 | -$779,902 | $3.29 | 17 |